

**REMARKS**

Pursuant to 37 C.F.R. § 1.98 copies of the U.S. patent documents (patents, application publications, and applications) are not being submitted herewith. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

Applicants note that Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination as per the requirements of 37 CFR § 1.97(b). Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: September 23, 2010

\_\_\_\_\_  
/Teresa Chen/  
Teresa Chen, Reg. No. 55,352  
Novo Nordisk Inc.  
Customer Number 23650  
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE